Consolidated Statements of Changes in Shareholders' Equity (Deficit) - USD ($)
Total
IPO
Private Placement
Common Class A
Common Class B
Ordinary shares
Ordinary shares
Common Class A
Ordinary shares
Common Class A
IPO
Ordinary shares
Common Class A
Private Placement
Ordinary shares
Common Class B
Additional paid-in capital
Additional paid-in capital
IPO
Additional paid-in capital
Private Placement
Accumulated other comprehensive income (loss)
Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2017           106,527,778                  
Beginning balance at Dec. 31, 2017 $ (41,268,515)         $ 10,653         $ 0     $ 118,696 $ (41,397,864)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Repurchase of shares (in shares)           (820,062)                  
Repurchase of shares (784,799)         $ (82)                 (784,717)
Vesting of restricted shares (Note 11) (in shares)           6,733,333                  
Vesting of restricted shares (Note 13) 165,711         $ 673         165,038        
Share-based compensation expense (Note 13) 2,253,350                   2,253,350        
Accretion on convertible redeemable preferred shares to redemption value (Note 11) (33,234,811)                   (2,418,388)       (30,816,423)
Net income (loss) 376,116                           376,116
Foreign currency translation adjustments (749,030)                         (749,030)  
Ending balance (in shares) at Dec. 31, 2018           112,441,049                  
Ending balance at Dec. 31, 2018 (73,241,978)         $ 11,244         0     (630,334) (72,622,888)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Repurchase of shares (in shares)           (100,000)                  
Repurchase of shares (84,440)         $ (10)         (84,430)        
Vesting of restricted shares (Note 11) (in shares)           6,733,333                  
Vesting of restricted shares (Note 13) 77,441         $ 673         76,768        
Share-based compensation expense (Note 13) 3,158,886                   3,158,886        
Reclassification of liability-classified awards to equity-classified awards (Note 13) 48,012                   48,012        
Accretion on convertible redeemable preferred shares to redemption value (Note 11) (50,714,953)                   (3,199,236)       (47,515,717)
Net income (loss) (6,177,438)                           (6,177,438)
Foreign currency translation adjustments $ (358,083)                         (358,083)  
Ending balance (in shares) at Dec. 31, 2019 119,074,382     0 0 119,074,382 0                
Ending balance at Dec. 31, 2019 $ (127,292,553)         $ 11,907 $ 0     $ 0 0     (988,417) (126,316,043)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Vesting of restricted shares (Note 11) (in shares)           2,805,557                  
Vesting of restricted shares (Note 13) 0         $ 280         (280)        
Share-based compensation expense (Note 13) 8,522,453                   8,522,453        
Conversion of ordinary shares to Class A and Class B Ordinary Shares (in shares)           (121,879,939) 45,700,000     76,179,939          
Conversion of ordinary shares to Class A and Class B Ordinary Shares 0         $ (12,187) $ 4,570     $ 7,617          
Accretion on convertible redeemable preferred shares to redemption value (Note 11) (193,465,743)                   (158,949,418)       (34,516,325)
Conversion of convertible redeemable preferred shares to Class A ordinary shares (Note 11) (in shares)             182,917,991                
Conversion of convertible redeemable preferred shares to Class A ordinary shares (Note 11) 483,436,142           $ 18,292       483,417,850        
Stock issued during period, new issues (in shares)               80,500,000 22,000,000            
Stock issued during period, new issues   $ 373,637,872 $ 110,000,000         $ 8,050 $ 2,200     $ 373,629,822 $ 109,997,800    
Net income (loss) (3,114,860)                           (3,114,860)
Foreign currency translation adjustments 2,929,387                         2,929,387  
Shares issued as part of an acquisition (in shares)             84,634                
Shares issued as part of an acquisition (Note 3) 850,000           $ 8       849,992        
Exercise of options (in shares)             7,632,431                
Exercise of options $ 960,464           $ 764       959,700        
Ending balance (in shares) at Dec. 31, 2020 415,014,994     338,835,056 76,179,938 0 338,835,056     76,179,939          
Ending balance at Dec. 31, 2020 $ 656,463,162         $ 0 $ 33,884     $ 7,617 $ 818,427,919     $ 1,940,970 $ (163,947,228)